ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Lonza Will Expand Viral Vaccines Unit

by Michael McCoy
May 23, 2011 | APPEARED IN VOLUME 89, ISSUE 21

Lonza will expand its viral-based therapeutics business with the construction of a clean room at its Houston facility. To open early next year, the clean room will house disposable bioreactors of up to 2,000 L that support late-stage viral vaccine and gene therapy projects. Lonza entered viral manufacturing in August 2010 through the acquisition of Houston-based Vivante GMP Solutions. The Swiss firm says viral vaccines are cheaper to make than traditional egg-based vaccines.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment